|
| Status |
Public on Jan 17, 2024 |
| Title |
Targeting HDAC6 to treat heart failure with preserved ejection fraction (HFpEF) |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| Web link |
https://www.nature.com/articles/s41467-024-45440-7
|
| |
|
| Citation(s) |
38409164 |
| |
| Submission date |
Dec 05, 2023 |
| Last update date |
Mar 11, 2024 |
| Contact name |
Farshad Farshidfar |
| E-mail(s) |
ffarshidfar@tenayathera.com
|
| Organization name |
Tenaya Therapeutics Inc.
|
| Street address |
171 Oyster Point Blvd Ste 500
|
| City |
South San Francisco |
| State/province |
CA |
| ZIP/Postal code |
94080 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL24247 |
Illumina NovaSeq 6000 (Mus musculus) |
|
| Samples (68)
|
|
| This SuperSeries is composed of the following SubSeries:
|
| GSE245034 |
Bulk RNA-seq comparison of TYA-018 HDAC6 inhibition vs SGLT2 inhibition vs vehicle after a 3-months long-term treatment in Mus Musculus to treat heart failure with preserved ejection fraction |
| GSE249409 |
RNA-seq comparison of HFD-mTAC model of heart failure with preserved ejection fraction vs control heart tissue in Mus Musculus |
| GSE249411 |
Bulk RNA-seq comparison of TYA018 HDAC6 inhibition vs vehicle after a single dose treatment in Mus Musculus to treat heart failure with preserved ejection fraction |
| GSE249412 |
Single nucleus RNA-seq comparison of TYA018 HDAC6 inhibition and Empagliflozin SGLT2 inhibition to treat heart failure with preserved ejection fraction |
|
| Relations |
| BioProject |
PRJNA1048993 |
Less...
More...